Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries.
- DOI
- 10.1186/s12913-022-08683-y
- Published
- 2022 Nov 4
- Container
- BMC health services research
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1186/s12913-022-08683-y,
title = {Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries.},
author = {Yoo HK and Byun HG and Caprioli F and Fumery M and Peyrin-Biroulet L and Sreedhar S and Potter J and Jang M},
year = {2022},
journal = {BMC health services research},
doi = {10.1186/s12913-022-08683-y},
url = {https://doi.org/10.1186/s12913-022-08683-y}
}RIS
TY - JOUR TI - Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries. AU - Yoo HK AU - Byun HG AU - Caprioli F AU - Fumery M AU - Peyrin-Biroulet L AU - Sreedhar S AU - Potter J AU - Jang M PY - 2022 JO - BMC health services research DO - 10.1186/s12913-022-08683-y UR - https://doi.org/10.1186/s12913-022-08683-y ER -
APA
HK, Y., HG, B., F, C., M, F., L, P., S, S., J, P., & M, J. (2022). Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries.. BMC health services research. https://doi.org/10.1186/s12913-022-08683-y
Source records
- pubmed · retrieved 2026-09-26T11:47:20.510Z